Diagenode

News

CRISPR/Cas9 press release
September 23, 2015

Diagenode’s CRISPR/Cas9 polyclonal antibody has been raised against the N-terminus of the Cas9 nuclease, extensively validated and optimized for excellent specificity and high yields in chromatin IP.

Read more

新闻

 查看所有新闻


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics